Lv11
10 积分 2023-02-18 加入
Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn's Disease: Results From the Phase 3 GRAVITI Study
1小时前
待确认
Beyond tumor necrosis factor and interleukin-12/23: The rise of interleukin-23 inhibitors in inflammatory bowel disease management
1小时前
求助中
Guselkumab in moderately to severely active ulcerative colitis: Another interleukin-23p19 subunit inhibitor or more?
1小时前
已完结
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study
26天前
已完结
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study
26天前
已完结
The Phenomenon of Anti-Drug Antibodies in Psoriasis: Mechanisms, Clinical Impact, and Therapeutic Strategies
3个月前
已完结
Defining On-Treatment Remission in Plaque Psoriasis: A Consensus Statement From the National Psoriasis Foundation
3个月前
已完结
皖公网安备34019202002308
